Oncology development

What longer follow-up revealed in the HARMONi trial

Review Insmed’s 12-month open-label TPIP findings in pulmonary arterial hypertension and what sites need for the PALM-PAH Phase 3 trial.

By Lampgen Clinical Research

1 min read · estimated

Sources
9.2 months23.2 months
Median Western follow-up at the primary and updated analyses

What the source reported

Summit’s July 2026 update to the Phase 3 HARMONi trial reported an overall survival hazard ratio of 0.76 in both the full trial population and the Western subgroup. The trial compared investigational ivonescimab plus chemotherapy with placebo plus chemotherapy in previously treated EGFR-mutated nonsquamous non-small cell lung cancer. The primary overall survival analysis had missed statistical significance.

What this means for trial teams

Western follow-up was shorter at the primary analysis. The later data help interpret the apparent regional difference. For clinical teams, the practical implication is to plan survival follow-up beyond treatment discontinuation, reconcile vital status before database cuts, and monitor follow-up completeness by region.

Sources

  1. Summit Therapeutics SEC filing
  2. Lampgen on LinkedIn

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?